Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single- Arm, Open-Label, Multi-Center Study

다국어 초록 (Multilingual Abstract)

Background: Removal of uremic toxins such as indoxyl sulfate by AST-120 is known to improve renal function and delay the initiation of dialysis in patients with advanced chronic kidney disease. However, it is unclear whether the addition of AST-120 to conventional treatments is effective in delaying the progression of renal dysfunction in patients with diabetic nephropathy.
Methods: A total of 100 patients with type 2 diabetes and renal dysfunction (serum creatinine levels ranging from 1.5 to 3.0 mg/dL) were recruited from eight centers in Korea and treated with AST-120 (6 g/day) for 24 weeks. The primary endpoint was improvement in renal function measured as the gradient of the reciprocal serum creatinine level (1/sCr) over time (i.e., the ratio of 1/sCr time slope for post- to pre-AST-120 therapy). A response was defined as a ratio change of the regression coefficient of 1/sCr ≤ 0.90.
Results: Renal function improved in 80.3% of patients (61/76) after 24 weeks of AST-120 treatment. There were no differences between responder and non-responder groups in baseline characteristics except for diastolic blood pressure (73.5 ± 9.5 mmHg in the responder group vs. 79.3 ± 11.1 mmHg in the non-responder group; P = 0.046). Serum lipid peroxidation level decreased significantly in the responder group (from 2.25 ± 0.56 μmol/L to 1.91 ± 0.72 μmol/L; P = 0.002) but not in the non-responder group.
Conclusion: The addition of AST-120 to conventional treatments may delay the progression of renal dysfunction in diabetic nephropathy. The antioxidant effect of AST-120 might contribute to improvement in renal function.

참고문헌 (Reference)

1 Shepler B, "Update on potential drugs for the treatment of diabetic kidney disease" 34 (34): 1237-1246, 2012

2 Sanaka T, "Therapeutic effects of oral sorbent in undialyzed uremia" 12 (12): 97-103, 1988

3 Niwa T, "Targeting protein-bound uremic toxins in chronic kidney disease" 17 (17): 1287-1301, 2013

4 Schulman G, "Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120" 22 (22): 299-308, 2018

5 Ichikawa I, "Renal antioxidant enzymes : their regulation and function" 45 (45): 1-9, 1994

6 Schulman G, "Randomized placebo-controlled EPPIC trials of AST-120 in CKD" 26 (26): 1732-1746, 2015

7 Sanaka T, "Protective effect of an oral adsorbent on renal function in chronic renal failure : determinants of its efficacy in diabetic nephropathy" 8 (8): 232-240, 2004

8 Shoji T, "Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function" 105 (105): c99-c107, 2007

9 Wilkinson CP, "Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales" 110 (110): 1677-1682, 2003

10 안재희, "Prevalence and Determinants of Diabetic Nephropathy in Korea: Korea National Health and Nutrition Examination Survey" 대한당뇨병학회 38 (38): 109-119, 2014

11 Cockcroft DW, "Prediction of creatinine clearance from serum creatinine" 16 (16): 31-41, 1976

12 Scott IA, "Non-inferiority trials : determining whether alternative treatments are good enough" 190 (190): 326-330, 2009

13 Hattori M, "Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury" 71 : S47-S50, 1999

14 Trevisan R, "Lipids and renal disease" 17 (17): S145-S147, 2006

15 Shimizu H, "Kremezin(AST-120)delays the progression of diabetic nephropathy in Japanese type 2 diabetic patients" 28 (28): 2590-, 2005

16 Niwa T, "Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis" 124 (124): 96-104, 1994

17 Owada S, "Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats" 28 (28): 446-454, 2008

18 Niwa T, "Indoxyl sulfate is a nephro-vascular toxin" 20 (20): S2-S6, 2010

19 Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man" 28 (28): 412-419, 1985

20 Akizawa T, "Effect of a carbonaceous oral adsorbent on the progression of CKD : a multicenter, randomized, controlled trial" 54 (54): 459-467, 2009

21 Yorioka N, "Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure" 30 (30): 467-475, 2002

22 Tuttle KR, "Diabetic kidney disease: a report from an ADA Consensus Conference" 37 (37): 2864-2883, 2014

23 박철휘, "Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives" 대한당뇨병학회 38 (38): 252-260, 2014

24 Remuzzi G, "Clinical practice. Nephropathy in patients with type 2 diabetes" 346 (346): 1145-1151, 2002

25 Ritz E, "Clinical manifestations and natural history of diabetic kidney disease" 97 (97): 19-29, 2013

26 Konishi K, "AST-120(Kremezin)initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects" 81 (81): 310-315, 2008

27 Mitch WE, "A simple method of estimating progression of chronic renal failure" 2 (2): 1326-1328, 1976

28 Cha RH, "A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction" 11 (11): 559-567, 2016

29 Levey AS, "A new equation to estimate glomerular filtration rate" 150 (150): 604-612, 2009